TD Waterhouse Canada Inc. Sells 4,173 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

TD Waterhouse Canada Inc. trimmed its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 90.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 425 shares of the company's stock after selling 4,173 shares during the quarter. TD Waterhouse Canada Inc.'s holdings in TransMedics Group were worth $26,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of TransMedics Group by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock worth $226,700,000 after acquiring an additional 40,860 shares during the period. FIL Ltd raised its holdings in shares of TransMedics Group by 28.0% during the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company's stock worth $62,372,000 after acquiring an additional 218,961 shares during the period. Geode Capital Management LLC raised its holdings in shares of TransMedics Group by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 772,744 shares of the company's stock worth $48,191,000 after acquiring an additional 8,954 shares during the period. Wasatch Advisors LP raised its holdings in shares of TransMedics Group by 83.3% during the fourth quarter. Wasatch Advisors LP now owns 441,354 shares of the company's stock worth $27,518,000 after acquiring an additional 200,603 shares during the period. Finally, Emerald Advisers LLC raised its holdings in shares of TransMedics Group by 146.3% during the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock worth $23,176,000 after acquiring an additional 220,804 shares during the period. 99.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of research analyst reports. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $122.70.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $90.19 on Tuesday. The stock has a 50 day moving average price of $74.67 and a 200 day moving average price of $77.10. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market capitalization of $3.05 billion, a PE ratio of 95.95 and a beta of 2.14.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.